Pfizer Contraceptive Pill Packaging Error Leads to Recall - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pfizer Contraceptive Pill Packaging Error Leads to Recall

ePT--the Electronic Newsletter of Pharmaceutical Technology

Following a packaging error affecting birth-control pills, Pfizer has issued a one-million pack recall and warned women in the United States who have been taking the medication during the last several months to “…consult with your physician and begin using a nonhormonal barrier method immediately.”

Lo/Ovral-28 (norgestrel and ethinyl estradiol) and norgestrel and ethinyl estradiol tablets, the generic version of its birth-control pill, are manufactured and packaged by Pfizer, commercialized by Akrimax Rx Products, and labeled under the Akrimax Pharmaceuticals brand. Both products may have been affected by a packaging error in which the placebo or inactive pill was placed incorrectly in some packs. The products are packaged in blister packs that contain 21 tablets of active ingredients and seven placebo tablets, but it is the order in which the tablets are taken that leads to correct dosing of the medication—an important factor in avoiding the risks of unwanted pregnancy. At press time, there was very limited information on the Akrimax website regarding the recall.

Although Pfizer indicates, based on an internal assessment, that 30 packs may have received an inexact count or inactive tablet, it has recalled 28 lots accounting for one million packs to remove any product that could have been affected by the error. In a press statement, Pfizer said, “We understand that this news can be very concerning and confusing for any woman who takes birth control pills to protect against unintended pregnancies.”


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here